Funding for this research was provided by:
National Institute of General Medical Sciences (1DP2OD020839)
National Institute of Allergy and Infectious Diseases (5U24AI118672)
Brigham and Women's Hospital (Shark Tank Pilot Grant)
Massachusetts Institute of Technology
Damon Runyon Cancer Research Foundation (DRG-2274-16)
National Institutes of Health (1R01AI138546, 1R33CA202820, 2U19AI089992, 2R01HL095791, 1U54CA217377, DE013023, HL095722, 1R01HL126554, 2P01AI039671, 1R01DA046277)
Searle Scholars Program
Arnold and Mabel Beckman Foundation (Beckman Young Investigator Award)
Kenneth Rainin Foundation (Breakthrough Award)
National Science Foundation (Graduate Research Fellowship Program)
Bill and Melinda Gates Foundation (OPP1116944, OPP1139972, OPP1137006)
National Human Genome Research Institute (2RM1HG006193)
Sloan Research Fellowship in Chemistry
Received: 30 March 2018
Accepted: 8 May 2018
First Online: 5 June 2018
Ethics approval and consent to participate
: Isolation of tissues, housing, and maintenance of animal colonies were all performed under the approval and guidelines of the MIT Committee on Animal Care or the Harvard Digestive Disease Center and Brigham and Women’s Gnotobiotic Core.
: JMK, RSL, and XY hold equity in Frequency Therapeutics, a company that has an option to license IP generated by JMK, RSL, and XY and that may benefit financially if the IP is licensed and further validated. The interests of JMK, RSL, and XY were reviewed and are subject to a management plan overseen by their institutions in accordance with their conflict of interest policies.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.